Palisade Bio, Inc. financial data

Symbol
PALI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
7750 El Camino Real, Suite 5200, Carlsbad, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Seneca Biopharma, Inc. (to 4/26/2021), Neuralstem, Inc. (to 1/23/2020)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 512 % -15.5%
Debt-to-equity 24.7 % +21.1%
Return On Equity -125 % -26.4%
Return On Assets -100 % -22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.18M shares -82.7%
Common Stock, Shares, Outstanding 966K shares -85.9%
Entity Public Float 11.6M USD +43.2%
Common Stock, Value, Issued 9K USD -87%
Weighted Average Number of Shares Outstanding, Basic 1.23M shares +187%
Weighted Average Number of Shares Outstanding, Diluted 1.23M shares +187%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
General and Administrative Expense 6.27M USD -4.21%
Operating Income (Loss) -14.8M USD -2.9%
Nonoperating Income (Expense) 642K USD -32.8%
Net Income (Loss) Attributable to Parent -14.2M USD -5.43%
Earnings Per Share, Basic 6.35 USD/shares +58.1%
Earnings Per Share, Diluted 6.35 USD/shares +58.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.4M USD -30.8%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD
Assets, Current 12.3M USD -29.3%
Property, Plant and Equipment, Net 4K USD -63.6%
Operating Lease, Right-of-Use Asset 142K USD -43.2%
Other Assets, Noncurrent 387K USD -34.6%
Assets 12.9M USD -29.6%
Accounts Payable, Current 514K USD -44.3%
Employee-related Liabilities, Current 288K USD -1.03%
Accrued Liabilities, Current 1.56M USD +160%
Liabilities, Current 2.84M USD +21.5%
Operating Lease, Liability, Noncurrent 24K USD -84.3%
Liabilities 2.92M USD +17.3%
Retained Earnings (Accumulated Deficit) -129M USD -212%
Stockholders' Equity Attributable to Parent 9.95M USD -37%
Liabilities and Equity 12.9M USD -29.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.18M USD +9.81%
Net Cash Provided by (Used in) Financing Activities 2.02M USD -54.4%
Common Stock, Shares Authorized 280M shares 0%
Common Stock, Shares, Issued 966K shares -85.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD -226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2K USD
Deferred Tax Assets, Valuation Allowance 29M USD +8.54%
Deferred Tax Assets, Gross 29.1M USD +8.17%
Operating Lease, Liability 154K USD -42.1%
Depreciation 1K USD 0%
Lessee, Operating Lease, Liability, to be Paid 163K USD -45.1%
Operating Lease, Liability, Current 130K USD +15%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 94K USD -30.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -71%
Lessee, Operating Lease, Liability, to be Paid, Year Three 93K USD
Deferred Tax Assets, Operating Loss Carryforwards 24.7M USD +8.92%
Additional Paid in Capital 139M USD +6.43%
Share-based Payment Arrangement, Expense 840K USD +46.1%
Interest Expense 15K USD +50%